Seattle Genetics (SGEN) 36.98 $SGEN
Burkitt Lymphoma - Pipeline Review, H1 2014
M2 - Mon May 12, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9w9t3k/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Burkitt Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Burkitt Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Seattle Genetics, Inc. - Constellation Pharmaceuticals, Inc. Drug Profiles: - SGN-CD19A - NSC-678515 - SH-7139 - Small Molecules To Inhibit BET For Cancer - HCQ/CLB-Loaded anti-CD20 BNP - M-921 - SH-7133 - SH-7129 - Andrographolide - Curacin A For more information visit http://www.researchandmarkets.com/research/9w...t_lymphoma
Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics
PR Newswire - Thu May 08, 8:10AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:
Seattle Genetics to Present at Upcoming Investor Conferences
Business Wire - Wed May 07, 8:01AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
29.9% Return Seen to Date on SmarTrend Seattle Genetics Call (SGEN)
Comtex SmarTrend(R) - Tue May 06, 9:41AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 2 months, Seattle Genetics has returned 29.95% as of today's recent price of $35.20.
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:10AM CDT
Shares of Seattle Genetics (SGEN) fell 11.2% in spite of the company???s better-than-expected first quarter results.
Seattle Genetics (SGEN) Is Today's Dead Cat Bounce Stock
at The Street - Mon May 05, 9:40AM CDT
Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 7:35PM CDT
Stocks closed modestly lower Friday, as violence in Ukraine's third-largest city raised the chances of more aggressive Russian intervention and whatever response Western nations would make to such a move. Favorable jobs data helped counteract the...
Nasdaq stocks posting largest percentage decreases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Seattle Genetics Falls 11.24% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri May 02, 4:43PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $34.02 to a high of $37.50. Yesterday, the shares fell 11.2%, which took the trading range below the 3-day low of $37.05 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Seattle Genetics, Inc. Shares Soured
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Seattle Genetics , a biotechnology company...
Seattle Genetics' Revenue Rises 19% on Adcetris Sales Growth
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 6:02PM CDT
Antibody-drug conjugate developer Seattle Genetics reported its first-quarter results after the closing bell this evening, giving hope to optimists that ADC-based companies could have a viable and potentially profitable platform over the long...
Seattle Genetics Reports First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:08PM CDT
---Conference Call Today at 4:30 p.m. ET-
Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics I
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:30AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for BioMarin , InterMune , and Seattle Genetics . BioMarin will hold an earnings call after the bell today Orphan drug specialist BioMarin will report...
Downtrend Call Working As Seattle Genetics Stock Falls 25.7% (SGEN)
Comtex SmarTrend(R) - Tue Apr 29, 9:14AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 2 months, Seattle Genetics has returned 25.70% as of today's recent price of $37.33.
Natural Killer Cell Lymphomas Clinical Trials Review 2014
M2 - Tue Apr 29, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xct7cn/natural_killer) has announced the addition of the "Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" report to their offering. Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" provides data on the Natural Killer Cell Lymphomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Natural Killer Cell Lymphomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Natural Killer Cell Lymphomas. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Natural Killer Cell Lymphomas Therapeutics Clinical Trials - Kirin Holdings Company, Limited - Takeda Pharmaceutical Company Limited - Seattle Genetics, Inc. - Mundipharma International Limited - Cell Medica Limited - Fred Hutchinson Cancer Research Center - National Cancer Institute - Samsung Medical Center - Sun Yat-sen University - FUDAN University - University of Washington - Case Comprehensive Cancer Center - City of Hope National Medical Center - West China Hospital - NK-cell Tumor Study Group For more information visit http://www.researchandmarkets.com/research/xc...ral_killer
Seattle Genetics Down 21.4% Since SmarTrend Downtrend Call (SGEN)
Comtex SmarTrend(R) - Mon Apr 21, 4:50PM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 1 month, Seattle Genetics has returned 21.40% as of today's recent price of $39.49.
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014
Business Wire - Wed Apr 16, 8:00AM CDT
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Premier Biomedical (BIEI) and the Wild West of Modern Medicine
ACCESSWIRE - Mon Apr 14, 9:25AM CDT
Whitefish, MT / April 14, 2014 / Premier Biomedical, Inc. and the Wild West of Modern Medicine
Burkitt Lymphoma - Pipeline Review, H1 2014
M2 - Mon May 12, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9w9t3k/burkitt_lymphoma) has announced the addition of the "Burkitt Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Burkitt Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Burkitt Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Burkitt Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Burkitt Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Seattle Genetics, Inc. - Constellation Pharmaceuticals, Inc. Drug Profiles: - SGN-CD19A - NSC-678515 - SH-7139 - Small Molecules To Inhibit BET For Cancer - HCQ/CLB-Loaded anti-CD20 BNP - M-921 - SH-7133 - SH-7129 - Andrographolide - Curacin A For more information visit http://www.researchandmarkets.com/research/9w...t_lymphoma
Biotech Equities Technical Momentum -- Research on Ironwood Pharma, Neurocrine Biosciences, Rigel Pharma, and Seattle Genetics
PR Newswire - Thu May 08, 8:10AM CDT
The trading session on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished at 16,518.54, up 0.72% and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the day 0.56% higher at 1,878.21. During the trading session eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day 0.23% higher at 668.01, and the index has advanced 2.50% in the previous three months. Investor-Edge has initiated coverage on the following equities: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Neurocrine Biosciences Inc. (NASDAQ: NBIX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) and Seattle Genetics Inc. (NASDAQ: SGEN). Free technical research on IRWD, NBIX, RIGL and SGEN can be downloaded upon signing up at:
Seattle Genetics to Present at Upcoming Investor Conferences
Business Wire - Wed May 07, 8:01AM CDT
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics' website at www.seattlegenetics.com in the Investors and News section.
29.9% Return Seen to Date on SmarTrend Seattle Genetics Call (SGEN)
Comtex SmarTrend(R) - Tue May 06, 9:41AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 2 months, Seattle Genetics has returned 29.95% as of today's recent price of $35.20.
Narrower-than-Expected Loss at Seattle Genetics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 05, 11:10AM CDT
Shares of Seattle Genetics (SGEN) fell 11.2% in spite of the company???s better-than-expected first quarter results.
Seattle Genetics (SGEN) Is Today's Dead Cat Bounce Stock
at The Street - Mon May 05, 9:40AM CDT
Trade-Ideas LLC identified Seattle Genetics (SGEN) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why Manitowoc, Endocyte, and Seattle Genetics Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 02, 7:35PM CDT
Stocks closed modestly lower Friday, as violence in Ukraine's third-largest city raised the chances of more aggressive Russian intervention and whatever response Western nations would make to such a move. Favorable jobs data helped counteract the...
Nasdaq stocks posting largest percentage decreases
AP - Fri May 02, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Seattle Genetics Falls 11.24% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri May 02, 4:43PM CDT
Seattle Genetics (NASDAQ:SGEN) traded in a range yesterday that spanned from a low of $34.02 to a high of $37.50. Yesterday, the shares fell 11.2%, which took the trading range below the 3-day low of $37.05 on volume of 3.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Why Seattle Genetics, Inc. Shares Soured
Sean Williams, The Motley Fool - Motley Fool - Fri May 02, 1:04PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Seattle Genetics , a biotechnology company...
Seattle Genetics' Revenue Rises 19% on Adcetris Sales Growth
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 6:02PM CDT
Antibody-drug conjugate developer Seattle Genetics reported its first-quarter results after the closing bell this evening, giving hope to optimists that ADC-based companies could have a viable and potentially profitable platform over the long...
Seattle Genetics Reports First Quarter 2014 Financial Results
Business Wire - Thu May 01, 3:08PM CDT
---Conference Call Today at 4:30 p.m. ET-
Today's Biotech Stocks to Watch: BioMarin Pharmaceutical Inc, InterMune, Inc. and Seattle Genetics I
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:30AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for BioMarin , InterMune , and Seattle Genetics . BioMarin will hold an earnings call after the bell today Orphan drug specialist BioMarin will report...
Downtrend Call Working As Seattle Genetics Stock Falls 25.7% (SGEN)
Comtex SmarTrend(R) - Tue Apr 29, 9:14AM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 2 months, Seattle Genetics has returned 25.70% as of today's recent price of $37.33.
Natural Killer Cell Lymphomas Clinical Trials Review 2014
M2 - Tue Apr 29, 5:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xct7cn/natural_killer) has announced the addition of the "Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" report to their offering. Natural Killer Cell Lymphomas Global Clinical Trials Review, H1, 2014" provides data on the Natural Killer Cell Lymphomas clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Natural Killer Cell Lymphomas. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Natural Killer Cell Lymphomas. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Institutions Participating in Natural Killer Cell Lymphomas Therapeutics Clinical Trials - Kirin Holdings Company, Limited - Takeda Pharmaceutical Company Limited - Seattle Genetics, Inc. - Mundipharma International Limited - Cell Medica Limited - Fred Hutchinson Cancer Research Center - National Cancer Institute - Samsung Medical Center - Sun Yat-sen University - FUDAN University - University of Washington - Case Comprehensive Cancer Center - City of Hope National Medical Center - West China Hospital - NK-cell Tumor Study Group For more information visit http://www.researchandmarkets.com/research/xc...ral_killer
Seattle Genetics Down 21.4% Since SmarTrend Downtrend Call (SGEN)
Comtex SmarTrend(R) - Mon Apr 21, 4:50PM CDT
SmarTrend identified a Downtrend for Seattle Genetics (NASDAQ:SGEN) on March 14th, 2014 at $50.24. In approximately 1 month, Seattle Genetics has returned 21.40% as of today's recent price of $39.49.
Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2014 Financial Results on May 1, 2014
Business Wire - Wed Apr 16, 8:00AM CDT
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its first quarter 2014 financial results on Thursday, May 1, 2014, after the close of financial markets. Following the announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:
Premier Biomedical (BIEI) and the Wild West of Modern Medicine
ACCESSWIRE - Mon Apr 14, 9:25AM CDT
Whitefish, MT / April 14, 2014 / Premier Biomedical, Inc. and the Wild West of Modern Medicine
